AbbVie Inc.
ABBVAPI behind this page
ABBV Q2 2025 request
Playground key active
/api/financials?ticker=ABBV&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 15,423 | 14,462 | +6.6% |
| Cost of Revenue | 4,346 | 4,202 | +3.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Foreign Exchange Forward | -29 | -10 | -190.0% |
| Selling, General & Administrative | 3,253 | 3,377 | -3.7% |
| Research And Development Expense Excluding Acquired In Process Cost | 2,131 | 1,948 | +9.4% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 823 | 937 | -12.2% |
Show Counterparty Name breakouts |
|||
| ADARx Pharmaceuticals, Inc. | 335 | — | — |
| Gubra A/S | 350 | — | — |
| Other Collaboration Arrangements · Collaborative Arrangement | 705 | 927 | -23.9% |
| Other Operating Income Expense Net | 24 | — | — |
| Total Costs & Expenses | 10,529 | 10,464 | +0.6% |
| Operating Income | 4,894 | 3,998 | +22.4% |
| Interest Income Expense Nonoperating Net | 678 | 506 | +34.0% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Treasury Lock | -5 | -6 | +16.7% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | -37 | -31 | -19.4% |
| Foreign Currency Transaction Gain Loss Before Tax | 23 | 1 | +2200.0% |
| Other Non-Operating Income (Expense) | 2,639 | 1,345 | +96.2% |
| Income Before Taxes | 1,554 | 2,146 | -27.6% |
| Income Tax Expense (Benefit) | 613 | 773 | -20.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income | 6 | 4 | +50.0% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | 8 | 7 | +14.3% |
| Net Income | 941 | 1,373 | -31.5% |
| Net Income Loss Attributable To Noncontrolling Interest | 3 | 3 | 0.0% |
| Net Income | 938 | 1,370 | -31.5% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income | 28 | 12 | +133.3% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | 29 | 24 | +20.8% |
| Retained Earnings | 938 | 1,370 | -31.5% |
| EPS (Basic) | 0.52 | 0.77 | -32.5% |
| EPS (Diluted) | 0.52 | 0.77 | -32.5% |
| Wtd Avg Shares (Basic) | 1,768 | 1,768 | 0.0% |
| Wtd Avg Shares (Diluted) | 1,771 | 1,771 | 0.0% |
| Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| All other | 603 | 810 | -25.6% |
| Alphagan/Combigan · Eye Care | 36 | 49 | -26.5% |
| Alphagan/Combigan · Non Us | 36 | 36 | 0.0% |
| Botox Cosmetic · Aesthetics | 692 | 729 | -5.1% |
| Botox Cosmetic · Non Us | 282 | 279 | +1.1% |
| Botox Cosmetic · US | 410 | 450 | -8.9% |
| Botox Therapeutic · Neuroscience | 928 | 814 | +14.0% |
| Botox Therapeutic · Non Us | 153 | 145 | +5.5% |
| Botox Therapeutic · US | 775 | 669 | +15.8% |
| Creon · US | 404 | 372 | +8.6% |
| Duodopa · Neuroscience | 97 | 113 | -14.2% |
| Duodopa · Non Us | 77 | 90 | -14.4% |
| Duodopa · US | 20 | 23 | -13.0% |
| Elahere · Non Us | 21 | — | — |
| Elahere · Oncology | 159 | 128 | +24.2% |
| Elahere · US | 138 | 128 | +7.8% |
| Epkinly · Non Us | 21 | 7 | +200.0% |
| Epkinly · Oncology | 70 | 36 | +94.4% |
| Humira · Immunology | 1,180 | 2,814 | -58.1% |
| Humira · Non Us | 378 | 454 | -16.7% |
| Humira · US | 802 | 2,360 | -66.0% |
| Imbruvica · Oncology | 754 | 833 | -9.5% |
| Imbruvica · US | 543 | 595 | -8.7% |
| Juvederm Collection · Aesthetics | 260 | 343 | -24.2% |
| Juvederm Collection · Non Us | 155 | 205 | -24.4% |
| Juvederm Collection · US | 105 | 138 | -23.9% |
| Linzess/Constella · Non Us | 11 | 10 | +10.0% |
| Linzess/Constella · Other Key Products | 258 | 221 | +16.7% |
| Linzess/Constella · US | 247 | 211 | +17.1% |
| Lumigan/Ganfort · Eye Care | 103 | 103 | 0.0% |
| Lumigan/Ganfort · Non Us | 51 | 61 | -16.4% |
| Lumigan/Ganfort · US | 52 | 42 | +23.8% |
| Mavyret · Non Us | 191 | 202 | -5.4% |
| Mavyret · Other Key Products | 375 | 369 | +1.6% |
| Mavyret · US | 184 | 167 | +10.2% |
| Other Aesthetics · Aesthetics | 327 | 318 | +2.8% |
| Other Aesthetics · Non Us | 45 | 43 | +4.7% |
| Other Aesthetics · US | 282 | 275 | +2.5% |
| Other Eye Care · Eye Care | 250 | 257 | -2.7% |
| Other Eye Care · Non Us | 106 | 108 | -1.9% |
| Other Eye Care · US | 144 | 149 | -3.4% |
| Other Neuroscience · Neuroscience | 55 | 62 | -11.3% |
| Other Neuroscience · Non Us | 4 | 5 | -20.0% |
| Other Neuroscience · US | 51 | 57 | -10.5% |
| Other Oncology · US | 2 | — | — |
| Ozurdex · Eye Care | 125 | 124 | +0.8% |
| Ozurdex · Non Us | 95 | 89 | +6.7% |
| Ozurdex · US | 30 | 35 | -14.3% |
| Qulipta · Neuroscience | 267 | 150 | +78.0% |
| Qulipta · Non Us | 30 | 4 | +650.0% |
| Qulipta · US | 237 | 146 | +62.3% |
| Rinvoq · Immunology | 2,028 | 1,430 | +41.8% |
| Rinvoq · Non Us | 576 | 413 | +39.5% |
| Rinvoq · US | 1,452 | 1,017 | +42.8% |
| Skyrizi · Immunology | 4,423 | 2,727 | +62.2% |
| Skyrizi · Non Us | 580 | 387 | +49.9% |
| Skyrizi · US | 3,843 | 2,340 | +64.2% |
| Ubrelvy · Neuroscience | 338 | 231 | +46.3% |
| Ubrelvy · Non Us | 8 | 4 | +100.0% |
| Ubrelvy · US | 330 | 227 | +45.4% |
| Venclexta · Non Us | 370 | 337 | +9.8% |
| Venclexta · Oncology | 691 | 637 | +8.5% |
| Venclexta · US | 321 | 300 | +7.0% |
| Vraylar · Neuroscience | 900 | 774 | +16.3% |
| Vraylar · Non Us | 2 | 1 | +100.0% |
| Vraylar · US | 898 | 773 | +16.2% |
| Vyalev · Neuroscience | 98 | 18 | +444.4% |
| Vyalev · Non Us | 76 | 18 | +322.2% |
| Vyalev · US | 22 | — | — |
| Interest Income | -62 | -220 | +71.8% |
| Comprehensive Income | 1,142 | 1,311 | -12.9% |
| Net Income Loss Available To Common Stockholders Basic | 928 | 1,360 | -31.8% |
| Interest Expense | 740 | 726 | +1.9% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 6,467 | 13,130 | -50.7% |
| Accounts Receivable | 12,637 | 11,724 | +7.8% |
Show Counterparty Name breakouts |
|||
| Janssen Biotech Inc. · Collaborative Arrangement | 227 | 256 | -11.3% |
| Inventory | 4,960 | 4,218 | +17.6% |
| Prepaid Expense And Other Assets | 5,197 | 4,717 | +10.2% |
| Total Current Assets | 29,261 | 33,816 | -13.5% |
| Non-Current Assets | |||
| Long Term Investments | 310 | 272 | +14.0% |
| Property, Plant & Equipment | 5,283 | 5,023 | +5.2% |
| Goodwill | 35,638 | — | — |
| Other Non-Current Assets | 9,659 | 9,197 | +5.0% |
| Total Assets | 137,182 | 141,937 | -3.4% |
| Intangible Assets | 51,745 | 58,663 | -11.8% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 50,396 | 56,446 | -10.7% |
| Licensing Agreements | 1,349 | 2,217 | -39.2% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 57,031 | 60,243 | -5.3% |
| Current Liabilities | |||
| Short Term Borrowings | 5,556 | — | — |
Show Short Term Debt Type breakouts |
|||
| 364-day Term Loan Credit Agreement | 2 | — | — |
| Commercial Paper | 3.6 | — | — |
| Commercial Paper With Original Maturities Greater Than Three Months | 2 | — | — |
| Long Term Debt And Capital Lease Obligations Current | 1,966 | 12,586 | -84.4% |
| Accounts Payable And Accrued Liabilities Current | 32,245 | 29,329 | +9.9% |
Show Counterparty Name breakouts |
|||
| Janssen Biotech Inc. · Collaborative Arrangement | 247 | 270 | -8.5% |
| Total Current Liabilities | 39,767 | 41,915 | -5.1% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 2,554 | 2,726 | -6.3% |
| Other Non-Current Liabilities | 32,040 | 32,427 | -1.2% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 62,959 | 58,048 | +8.5% |
| Minority Interest | 45 | 43 | +4.7% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 18 | 18 | 0.0% |
| Treasury Stock Value | -9,147 | -7,838 | -16.7% |
| Additional Paid In Capital Common Stock | 21,987 | 20,879 | +5.3% |
| Retained Earnings | -11,503 | -3,768 | -205.3% |
| Accumulated Other Comprehensive Income | -1,538 | -2,513 | +38.8% |
| Total Stockholders' Equity | -183 | 6,778 | -102.7% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -138 | 6,821 | -102.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest | -662 | -1,470 | +55.0% |
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -576 | -1,659 | +65.3% |
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest | 132 | 260 | -49.2% |
| Accumulated Other Comprehensive Income | -1,538 | -2,513 | +38.8% |
| Additional Paid In Capital | 21,987 | 20,879 | +5.3% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -1,538 | -2,513 | +38.8% |
| Common Stock | 18 | 18 | 0.0% |
| Net investment hedging activities | -432 | 356 | -221.3% |
| Noncontrolling Interest | 45 | 43 | +4.7% |
| Retained Earnings | -11,503 | -3,768 | -205.3% |
| Treasury Stock Common | -9,147 | -7,838 | -16.7% |
| Total Liabilities & Equity | 137,182 | 141,937 | -3.4% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 367 | 367 | 0.0% |
| Amortization Of Intangible Assets | 3,722 | 3,838 | -3.0% |
| Deferred Income Taxes | -300 | -405 | +25.9% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 4,313 | 2,136 | +101.9% |
| Payment For Contingent Consideration Liability Operating Activities | -1,408 | -876 | -60.7% |
| Stock-Based Compensation | 589 | 566 | +4.1% |
| Non Cash Litigation Reserve Adjustments Net Of Cash Payments | -750 | 27 | -2877.8% |
| Other Non-Cash Items | 96 | -53 | +281.1% |
| Change in Accounts Receivable | -1,496 | -524 | -185.5% |
| Change in Inventory | -211 | -127 | -66.1% |
| Change in Prepaid & Other Assets | -257 | 309 | -183.2% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -181 | -1,337 | +86.5% |
| Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable | -997 | -1,456 | +31.5% |
| Net Cash from Operations | 6,788 | 6,311 | +7.6% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | -204 | -9,199 | +97.8% |
| Payments To Acquire Other Investments | -1,274 | -1,033 | -23.3% |
| Capital Expenditures | -504 | -434 | -16.1% |
| Payments To Acquire Marketable Securities | -22 | -22 | 0.0% |
| Proceeds From Sale Maturity And Collections Of Investments | 39 | 9 | +333.3% |
| Other Investing Activities | 49 | -11 | +545.5% |
| Net Cash from Investing | -1,916 | -10,690 | +82.1% |
| Financing Activities | |||
| Proceeds From Repayments Of Commercial Paper | 1,549 | — | — |
| Proceeds From Short Term Debt | 4,007 | 5,008 | -20.0% |
| Proceeds From Issuance Of Long Term Debt | 3,994 | 14,963 | -73.3% |
| Repayments Of Long Term Debt And Capital Securities | -6,780 | -3,448 | -96.6% |
| Debt Issuance Costs | -23 | -99 | +76.8% |
| Payments Of Dividends | -5,835 | -5,522 | -5.7% |
| Share Repurchases | -973 | -1,333 | +27.0% |
| Proceeds From Stock Options Exercised | 61 | 137 | -55.5% |
| Proceeds From Payments For Other Financing Activities | 32 | 24 | +33.3% |
| Net Cash from Financing | -3,968 | 4,722 | -184.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 39 | -27 | +244.4% |
| Net Change in Cash | 943 | 316 | +198.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 6,467 | 13,130 | -50.7% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.